Moleculin Biotech Inc banner

Moleculin Biotech Inc
NASDAQ:MBRX

Watchlist Manager
Moleculin Biotech Inc Logo
Moleculin Biotech Inc
NASDAQ:MBRX
Watchlist
Price: 2.32 USD Market Closed
Market Cap: $11.4m

During the last 3 months Moleculin Biotech Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 44% over this period (open performance analysis).

The last transaction was made on Jun 23, 2025 by Klemp Walter V , who bought 250k USD worth of MBRX shares.

Last Transactions:
Klemp Walter V
$+10k
Foster Jonathan P.
$+4k
Foster Jonathan P.
$+53.1
George Robert E.
$+26.9
Klemp Walter V
$+346.4
Klemp Walter V
$+153.7
Klemp Walter V
$+69
Klemp Walter V
$+67.4
Klemp Walter V
$+220.1
Klemp Walter V
$-74.9
Priebe Waldemar
$-74.9
Klemp Walter V
$+4.1
Northcut Jacqueline
$+0
George Robert E.
$+0
Foster Jonathan P.
$+3.5
View All Transactions

During the last 3 months Moleculin Biotech Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 44% over this period (open performance analysis).

The last transaction was made on Jun 23, 2025 by Klemp Walter V , who bought 250k USD worth of MBRX shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
2
14k USD

Moleculin Biotech Inc
Insider Trading Chart

Moleculin Biotech Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Moleculin Biotech Inc
Last Insider Transactions

Global
Insiders Monitor

Moleculin Biotech Inc
Glance View

Market Cap
11.4m USD
Industry
Biotechnology

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2016-06-02. The firm has a pipeline of clinical programs for the treatment of highly resistant cancers and viruses. The company has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066 Portfolio (including lead drug candidates WP1066 and WP1220) represents a class of agents capable of hitting multiple targets, including the activated form of a key oncogenic transcription factor, STAT3. WP1066 is its flagship Immune/Transcription Modulator. An analog of WP1066, referred to as WP1220, is related to the use of the molecule in the topical treatment of psoriasis. The firm's WP1122 Portfolio and similar molecules focused on inhibitors of glycolysis and glycosylation.

MBRX Intrinsic Value
1.36 USD
Overvaluation 41%
Intrinsic Value
Price $2.32

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett